Objective: To summarize the state of the art during the year 2016 in the areas related to consumer health informatics and education with a special emphasis in secondary use of patient data. Methods: We conducted a systematic review of articles published in 2016, using PubMed with a predefined set of queries. We identified over 320 potential articles for review. Papers were considered according to their relevance for the topic of the section. Using consensus, we selected the 15 most representative papers, which were submitted to external reviewers for full review and scoring. Based on the scoring and quality criteria, five papers were finally selected as best papers Results: The five best papers can be grouped in two major areas: 1) methods and tools to identify and collect formal requirements for secondary use of data, and 2) innovative topics highlighting the interest of carrying on "secondary" studies on patient data, more specifically on the data self-expressed by patients through social media tools. Regarding the formal requirements about informed consent, the selected papers report a comparison of legal aspects in European countries to find a common and unified grammar around the concept of "data donation". Regarding innovative approaches to value patient data, the selected papers report machine learning algorithms to extract knowledge from patient experience and satisfaction with health care delivery, drug and medication use, treatment compliance and barriers during cancer disease, or acceptation of public health actions such as vaccination. Conclusions: Secondary use of patient data (apart from personal health care record data) can be expressed according to many ways. Requirements to allow this secondary use have to be harmonized between countries, and social media platforms can be efficiently used to explore and create knowledge on patient experience with health problems or activities. Machine learning algorithms can explore those massive amounts of data to support health care professionals, and institutions provide more accurate knowledge about use and usage, behaviour, sentiment, or satisfaction about health care delivery.
Introduction
For this 26 th edition of the Yearbook of Medical Informatics, we had to adapt the special topic "Learning from experience: secondary use of patient data" to the section "Education and Consumer Health Informatics". Secondary use of data refers, for instance, to the use for research of data contained in records and collected for a purpose different from the one of the research itself. Secondary use of data has been described in common fields, such as school records, for example, originally produced for educational purposes, but now proposed for use in research. This issue becomes of concern when data can be linked to individuals, and becomes critical when the possibility exists that individuals can be identified in the published reports [1] . From a patient point of view, secondary use of health data consists in using personal health information (PHI) outside the direct health care delivery process [2] . To populate this section, we merged this original definition with the use of data the patient expresses about him/herself when using social media tools for varied purposes such as, for instance, healthcare delivery experience [3] , medication use, abuse, or misuse [4, 5, 6] , e-cigarette experience [7] , emotions, sentiments and feelings [8, 9] , experience with a specific disease [10] or a public health recommendation [11] , or daily health behaviours [12] . These data are not natively part of any personal health record, but may be voluntarily delivered by the patient to public and anonymous recipients. This unstructured data is now collected, extracted, and analysed by researchers with tools used to explore massive datasets for public health research [13, 14] . As in previous years, we have reviewed the literature in the area of consumer health informatics and education. This synopsis covers the best papers selected for the section "Consumer Health Informatics and Education" and provides a wide overview of various aspects of secondary use of data reflecting the patient experience. process"[All Fields] OR "social competition"[All Fields] OR "social norm"[All Fields] OR "social feedback"[All Fields] OR "social influence"[All Fields] OR "social comparison"[All Fields] OR "social network"[All Fields] OR "discussion group"[All Fields] OR "support group"[All Fields] OR "social support"[All Fields] OR "community network"[All Fields] OR "online community"[All Fields]) 5. AND ("missing data"[All Fields] OR "erroneous data"[All Fields] OR "uninterpretable data"[All Fields] OR "inconsistency"[All Fields] OR "inconsistencies"[All Fields] OR "completeness"[All Fields]) 6. AND ("privacy"[All Fields] OR "im- The results section bellow describes the different steps applied to filter the retrieved results until the final selection.
3 Results Table 1 summarizes the results of the different combinations of the previous nine query components. It should be noted that the combination of all the components is void and some combinations produced overly broad returns. Consequently, we selected five sets of query combinations that included 320 articles, which were reviewed by the section editors. A list of 15 candidate best papers was finally selected. Section editors used four selection criteria: 1) relevance regarding the 2017 yearbook special topic "Learning from experience: secondary use of patient data"; 2) nature of the problem addressed: legal aspects and requirements, methods and tools, healthcare topic; 3) level of evidence if appropriate; and 4) level of innovative approach.
The 15 papers were then reviewed by an international group of experts according to the Yearbook selection process. The 15 papers selected as candidate best papers can be grouped into two major areas: 1) methods and tools to identify and collect formal requirements for secondary use, and 2) innovative topics highlighting the interest of carrying on "secondary" studies on patient data.
Section editors presented the rationale on the impact and relevance of candidate best papers at the selection meeting of the Yearbook editorial committee. Section editors weighed the quality of the research and the relevance to the special topic as
Methodology
We used PubMed to conduct our review. Following the methodology from previous years, we used the following query to capture relevant papers about consumer health informatics and education. This query is based on a core (components 1, 3, 4, 6, 8) and variants expressed and designed to fit the main year topic (2, 5, 7, 9) 
Identifying and Collecting Formal Requirements for Data Donation
One of the major aspects discussed in the returned papers included the need of a formal framework for obtaining patient consent for biobanking and of the legal requirements for reusing available biomaterial and data. The concept of "data donor" is clearly expressed by Wilbanks and Topol in [15] : "at first, data donors may predominantly include those with personal incentives, or those who are philosophically driven to share their health data, for instance through being part of the Quantified Self community, which aims to use technology to measure all aspects of our daily lives. Such early advocates for sharing could help to change norms by pushing for clearer messaging around consent and by raising awareness about what is at stake." Further, ethical consequences arising from the privatization of health information were discussed [15] . This paper also highlights the difficulties of complying with legal requirements because of their heterogeneity among countries, especially in Europe. The selected best paper in this group also provides a good discussion on how to support secondary use of personal health data by enabling electronic informed consent: [3] . The authors concluded that their approach can be a way to complement the results of classical population-based surveys, for example by obtaining nearly real-time feedback from patients. They also expect the use of social media to be implemented in institutions that have developed a digital relationship with their patients and other interested parties, such as family members. Other authors have used similar approaches to better understand barriers to treatment [10] , side effects of drugs [9] , and vaccine hesitancy [11] . The selected best papers in this group are: 
Conclusions
Our synopsis shows the emergence of high quality research and initiatives focusing on the value of secondary data usage in the health domain, including to a greater extend consumer-generated data. Despite the growing importance of secondary data usage, most articles report on pilots and small studies showing that we are still far from massive adoption in day-to-day health practice. This lack of massive adoption is apparently the result of many socio-ethical barriers and concerns, as explained in Wilbanks and Topol [15] , and Safran, et al., [2] . As explained by Wilbanks and Topol [15] , uneven developments of datasets for secondary usage might lead to the privatization of health data. An approach to tackle most of those socio-ethical concerns is to adhere to the principles of participatory medicine and shared decision-making. Kondylakis, et al., gave a successful experience of that approach in a study incorporating patients as data donors in the processes of medical decision-making [16] . Although several studies have reported on the development of automated approaches to analyse tobacco and e-cigarette-related tweet content, and to identify adverse effects associated with the medical use of pharmaceutical drugs, there have been very few attempts to apply automated content analysis techniques to analyse drug abuse-related tweets. This lack of research is partially related to the fact that drug-related content adds another layer of ambiguity and difficulty in the development of automated techniques because of the pervasive use of slang terminology and implied meanings. For the words that suggest a particular sentiment, traditional approaches that use sentiment lexicons may not perform well, and machine learning techniques, trained using manually coded data, could increase the accuracy of sentiment identification in drug-related tweets. The purpose of this study was to describe the development and performance of machine learning classifiers to automatically identify tweets by the type of communication (personal, official/media, or retail) and sentiment (positive, negative, or neutral) expressed in cannabis-and synthetic cannabinoid-related tweets. To reach a sample size of 4,000 tweets for the manually-labelled data set for machine learning, more than 8,000 tweets were manually reviewed and filtered using QDA Miner. The tweets for manual coding were extracted from the pool of 15,623,869 tweets that were collected by eDrugTrends between May and November 2015. The sample of 4,000 manually-labelled tweets was split into two subsamples, 1,000 were used to train a source classifier, and 3,000 were allocated for sentiment classification. The most discriminative unigram and bigram features that were identified by chi-square test reflect thematic groups as pertinent to sentiment categories: "want," "love," "need" for positive, in contrast to "don't," "shit," "fake" for negative tweets. But the sentiment classifier tended to incorrectly classify tweets that expressed an opposing opinion to negative thoughts or actions related to cannabis use or its legalization. Furthermore, humorous and sarcastic tweets were also more difficult to classify correctly by the classifier. The identification of sentiment in personal, user-generated tweets is more relevant for drug abuse epidemiology research To date, most studies examining barriers to care for diverse populations have been conducted within registry-or claims-based cohorts. Additional smaller studies using surveys, focus groups, and medical records are often limited to a single geographic area or institution and may not necessarily generalize across diverse populations. Furthermore, most surveys have structured formats and are subject to recall bias. Social media has been recognized as a potential source of patient data often underrepresented in studies using conventional research methodologies, emerging thus as a rich, yet largely untapped, resource for understanding what patients are candidly saying about their experiences and treatments. The purpose of this study was to utilize machine learning to identify key issues and themes that patients with breast cancer were sharing online, focusing on the barriers to treatment. Postings from a 365-day period, ending on January 31, 2015, on message boards, blogs, topical sites, content sharing sites, and social networks were examined. 3,200,128 unique posts that discussed breast cancer were identified. The analyses were limited to the 1,024,041 (32 %) posts about treatment. When possible, a phase of treatment (pre-diagnosis, diagnosis, assessment, decision to treat, or treatment) was identified by tagging posts based on cues for a user's current situation through topical keywords and relevant self-reported experiences yielding 627,381 posts. Among these posts, overarching themes and treatment barriers were assigned for 387,238 (62% of 627,381). Organizational barriers generally increased from pre-diagnosis (6% of posts) to diagnosis (13%) and remained high during assessment (28%), decisions to treat (21%), and treatment (29%). Sociocultural barriers decreased over the treatment trajectory (24% of posts in the pre-diagnosis phase to 18-20% of posts about treatments) as did psychological barriers (43% to 19-25%). Situational barriers remained relatively constant over the treatment trajectory and were reported in a quarter of posts. For emotional barriers, most conversations reported fears, anxiety, denial, and depression. The most common belief-related sentiments were spiritual/religious (41%), although other prominent themes included misinformation (30%) and preferences/perceptions (29%). The most common physical concerns expressed were side effects (40%), followed by physical limitations (31%) and body changes (29%). Resource concerns included posts about insurance (49%), costs (33%), and logistics of treatment (18%). Dominant concerns raised within posts about healthcare perception barriers included poor communication (36 %), trust (22%), accessibility of services (21%), and negative experiences (21%). Among posts related to relationship barriers, the most dominant issues included problems with intimacy (35%), friends (34%), and children (31%). Duration and process barriers were categorized as issues with the regimens prescribed (41%), duration of treatment (23%), effects of the after treatment (19%), and complexity of care (17%). In 9,465 posts, users suggested that they refused recommended treatments that were recommended for their breast cancer. With this new type of "social intelligence" for research, mining the vast repository of unstructured big data for insight into patients' concerns and experiences, the authors learned about barriers to care for a large and diverse population of users. Experiences and perception of patients receiving healthcare as well as the necessity for healthcare stakeholders to measure and report outcomes are usually based on structured questionnaires. Limitations of these surveys include significant time lag between an outcome and a report of that outcome, and low response rates. As Twitter is actively used by one out of five adults, the authors sought to identify and analyse the content of posts sent to hospitals as a novel real-time measure of quality, supplementing traditional survey-based approaches. Hawkins, et al., assessed the use of Twitter as a supplemental data stream for measuring patient-perceived quality of care in US hospitals and for comparing patient sentiments about hospitals with established quality measures. A machine learning approach was used to classify tweets associated with patient experiences. Of the tweets directed to 2,349 US hospitals having an account on Twitter, over the period 1 October 2012 to 30 September 2013, 404,065 were analysed. Sentiment of patient experience was calculated for these tweets using natural language processing (the open source Python library TextBlob). A total of 11,602 tweets were manually categorised into patient experience topics, including food, money, pain, general, room condition, time, communication, discharge, medication instructions, side effects. Finally, 297 hospitals, representing 111 unique Twitter accounts with at least 50 patient-experience tweets were surveyed to understand how they use Twitter to interact with patients. The authors focused on the percentage of patients who rated a hospital at the highest levels on a validated scale of quality of care. The second validated measure of quality of care was the Hospital Compare 30-day hospital readmission rate calculated from the period 1 July 2012-30 June 2013 (https://www. medicare.gov/hospitalcompare/search.html). Roughly half of the hospitals in the US have a presence on Twitter (50.2%). Of the 297 surveyed hospitals, half responded and all confirmed that they closely monitor social media and interact with users. Of the tweets directed toward these hospitals, 34,725 (9.4%) were related to patient experiences, covering diverse topics. The top three topics discussed were: time management, money concerns, and communication with staff. Analyses limited to hospitals with at least 50 patient-experience tweets revealed that they were more active on Twitter, more likely to be below the national median of Medicare patients (p<0.001) and above the national median for nurse/patient ratio (p=0.006), and to be a non-profit hospital (p<0.001). After adjusting for hospital characteristics, they found that Twitter sentiment was not associated with Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS) ratings; however, having a Twitter account was associated with HCAHPS score, although there was a weak association with 30-day hospital readmission rates (p=0.003). The authors showed that monitoring Twitter provides useful, unsolicited, and real-time data that might not be captured by traditional feedback mechanisms. Tweets describing patient experiences in hospitals cover a wide range of patient care aspects and can be identified using automated approaches. The authors recommended that patients, researchers, and policy makers also attempt to utilise this data stream to understand the experiences of healthcare consumers and the quality of care they receive. The purpose of this paper was to study the current practices for obtaining consent for biobanking and the legal requirements for reusing the available biomaterial and data in EU. The authors present a novel modular IT tool named "Donor's Support Tool" in order to ensure that patients actively provide and update their consent according to applicable national laws, thus enabling the secondary use of data and biomaterial. The legal landscape for the secondary use of biomaterial and data in the European Union is complex. There is no harmonized European regulation that covers both the processing and use of biosamples and associated personal or clinical data at the same time. Different regimes apply to each EU member. At present, the use of personal data enjoys the more harmonized framework. Informed consent is one of the best-known elements of medical ethics and bioethics, and is widely utilized in clinical practice and clinical research. But there are various types of consent: the consents that applies to a specific purpose or research study, the consent that is partially restricted to a domain of purposes or types of research studies, the consent that is multi-layered, wherein consent can apply to a number of unnamed or unspecified purposes or studies, or the broad consent which applies to any purpose or research study, named or unnamed. In clinical trials, only the specific consent is allowed, while different approaches, ranging from specific to broad, or even simply 'presumed' consent, could be applied in the processing of human tissues among EU member states. Similarly, for personal data processing, multiple approaches could possibly apply in the EU member states. The EU Clinical Trial Regulation (EU No 536/2014, https:// ec.europa.eu/health/human-use/clinical-trials/regulation_en) requires that consent for a participation in a clinical trial be in a written form. National data protection laws usually require an explicit and written consent for the processing of sensitive data, except in the UK and Austria where no specific formal requirement has been set up. Regarding the identification and the authentication of the consent subject, even if a qualified electronic signature is desired, the usage of such signatures is not widespread among the European population. Transforming the legal requirements into information technology requirements, the authors designed and implemented the IT platform enabling citizens to actively provide and update their consent in real time. The three modules (personal information management system, donor's generation module, and donor's decision module) place participants at the heart of decision-making and allow individuals to tailor and manage their own consent preferences. Comparisons with six other relevant approaches are provided: SecureConsent, Mytrus, Educonsent, iMed-Consent, FORCS e-consent and Consentir. The system was also tested by the University College of London using retrospective data.
